Advice
following a full submission
Zonisamide (Zonegran) is accepted for restricted use within NHS Scotland as adjunctive therapy in adult patients with partial seizures, with or without secondary generalisation.
It should be initiated only by physicians who have appropriate experience in the treatment of epilepsy and should be used principally in patients who have not benefited from treatment with an older anti-convulsant drug such as carbamazepine or sodium valproate, or for whom these drugs are unsuitable because of contra-indications, interaction or poor tolerance.
Download detailed advice66KB (PDF)
Medicine details
- Medicine name:
- Zonisamide hard capsules 25 mg, 50 mg, 100 mg (Zonegran®)
- SMC ID:
- 216/05
- Indication:
- Epilepsy
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 December 2005